UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Can a Shift in Fuel Energetics Explain the Beneficial Cardiorenal Outcomes in the EMPA-REG OUTCOME Study? A Unifying Hypothesis

Diabetes care, 2016-07, Vol.39 (7), p.1115-1122

2016

Volltextzugriff (PDF)

Regulation of Substrate Utilization by the Mitochondrial Pyruvate Carrier

Molecular cell, 2014-11, Vol.56 (3), p.425-435

2014

Volltextzugriff (PDF)

Efficacy of GLP-1 Receptor Agonists and DPP-4 Inhibitors: Meta-Analysis and Systematic Review

Clinical therapeutics, 2012-06, Vol.34 (6), p.1247-1258.e22

2012

Volltextzugriff (PDF)

Exploring the potential of the SGLT2 inhibitor dapagliflozin in type 1 diabetes: a randomized, double-blind, placebo-controlled pilot study

Diabetes care, 2015-03, Vol.38 (3), p.412-419

2015

Volltextzugriff (PDF)

Altered Myokine Secretion Is an Intrinsic Property of Skeletal Muscle in Type 2 Diabetes

PloS one, 2016-07, Vol.11 (7), p.e0158209-e0158209

2016

Volltextzugriff (PDF)

AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY POSITION STATEMENT ON THE ASSOCIATION OF SGLT-2 INHIBITORS AND DIABETIC KETOACIDOSIS

Endocrine practice, 2016-06, Vol.22 (6), p.753-762

2016

Volltextzugriff (PDF)

American association of clinical endocrinologists and american college of endocrinology - clinical practice guidelines for developing a diabetes mellitus comprehensive care plan - 2015

Endocrine practice, 2015-04, Vol.21 Suppl 1, p.1-87

2015

Volltextzugriff (PDF)

Thiazolidinediones are acute, specific inhibitors of the mitochondrial pyruvate carrier

Proceedings of the National Academy of Sciences - PNAS, 2013-04, Vol.110 (14), p.5422-5427

2013

Volltextzugriff (PDF)

Uromodulin mRNA from Urinary Extracellular Vesicles Correlate to Kidney Function Decline in Type 2 Diabetes Mellitus

American journal of nephrology, 2018-01, Vol.47 (5), p.283-291

2018

Volltextzugriff (PDF)

Astaxanthin, a natural antioxidant, lowers cholesterol and markers of cardiovascular risk in individuals with prediabetes and dyslipidaemia

Diabetes, obesity & metabolism, 2023-07, Vol.25 (7), p.1985-1994

2023

Volltextzugriff (PDF)

Retinol-Binding Protein 4 and Insulin Resistance in Lean, Obese, and Diabetic Subjects

The New England journal of medicine, 2006-06, Vol.354 (24), p.2552-2563

2006

Volltextzugriff (PDF)

Adiponectin: More than just another fat cell hormone?

Diabetes care, 2003-08, Vol.26 (8), p.2442-2450

2003

Volltextzugriff (PDF)

Adiponectin in health and disease

Diabetes, obesity & metabolism, 2007-05, Vol.9 (3), p.282-289

2007

Volltextzugriff (PDF)

Effects of Exenatide (Exendin-4) on Glycemic Control Over 30 Weeks in Sulfonylurea-Treated Patients With Type 2 Diabetes

Diabetes care, 2004-11, Vol.27 (11), p.2628-2635

2004

Volltextzugriff (PDF)

Apolipoprotein J is a hepatokine regulating muscle glucose metabolism and insulin sensitivity

Nature communications, 2020-04, Vol.11 (1), p.2024-2024, Article 2024

2020

Volltextzugriff (PDF)

Efficacy and Safety of Canagliflozin, a Sodium-Glucose Cotransporter 2 Inhibitor, as Add-on to Insulin in Patients With Type 1 Diabetes

Diabetes care, 2015-12, Vol.38 (12), p.2258-2265

2015

Volltextzugriff (PDF)

Improved glycemic control with minimal systemic metformin exposure: Effects of Metformin Delayed-Release (Metformin DR) targeting the lower bowel over 16 weeks in a randomized trial in subjects with type 2 diabetes

PloS one, 2018-09, Vol.13 (9), p.e0203946-e0203946

2018

Volltextzugriff (PDF)

Effect of the dual peroxisome proliferator-activated receptor-α/γ agonist aleglitazar on risk of cardiovascular disease in patients with type 2 diabetes (SYNCHRONY): a phase II, randomised, dose-ranging study

The Lancet (British edition), 2009-07, Vol.374 (9684), p.126-135

2009

Volltextzugriff (PDF)

Sodium-Glucose Cotransporter Inhibitors: Effects on Renal and Intestinal Glucose Transport: From Bench to Bedside

Diabetes care, 2015-12, Vol.38 (12), p.2344-2353

2015

Volltextzugriff (PDF)

(−)-Epicatechin rich cocoa mediated modulation of oxidative stress regulators in skeletal muscle of heart failure and type 2 diabetes patients

International journal of cardiology, 2013-10, Vol.168 (4), p.3982-3990

2013

Volltextzugriff (PDF)

SGLT2 inhibition — a novel strategy for diabetes treatment

Nature reviews. Drug discovery, 2010-07, Vol.9 (7), p.551-559

2010

Volltextzugriff (PDF)

Poor medication adherence in type 2 diabetes: recognizing the scope of the problem and its key contributors

Patient preference and adherence, 2016-01, Vol.10, p.1299-1307

2016

Volltextzugriff (PDF)

Myokine Regulation of Insulin Secretion: Impact of Inflammation and Type 2 Diabetes

Frontiers in physiology, 2020-01, Vol.10, p.1608-1608

2020

Volltextzugriff (PDF)

Effects of (−)-epicatechin on molecular modulators of skeletal muscle growth and differentiation

The Journal of nutritional biochemistry, 2014-01, Vol.25 (1), p.91-94

2014

Volltextzugriff (PDF)

SGLT inhibitor adjunct therapy in type 1 diabetes

Diabetologia, 2018-10, Vol.61 (10), p.2126-2133

2018

Volltextzugriff (PDF)

1 – 25 von 744

Suche als RSS-Feed

Aktive Filter

SpracheFranzösisch

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(619)
Mit Volltextzugriff
(603)

Publikationsform

1 weiteren anzeigen...

Weniger anzeigen...

Sprache

Englisch
(743)
Japanisch
(3)

Erscheinungsjahr

n.n

Thema

Science & Technology
(416)
Life Sciences & Biomedicine
(334)
Humans
(311)
Male
(196)
Female
(165)
Biological And Medical Sciences
(161)
Middle Aged
(147)
Medical Sciences
(143)
Endocrinology & Metabolism
(131)
Adult
(130)
Diabetes
(95)
Animals
(78)
Aged
(77)
Diabetes Mellitus, Type 2 - Drug Therapy
(69)
Endocrinopathies
(69)
Diabetes. Impaired Glucose Tolerance
(61)
Endocrine Pancreas. Apud Cells
(61)
Insulin
(60)
Type 2 Diabetes
(57)
Hypoglycemic Agents - Therapeutic Use
(55)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(1)
... seit 90 Tagen
(4)

Menü

Weitere Dienste

Einstellungen

Can a Shift in Fuel Energetics Explain the Beneficial Cardiorenal Outcomes in the EMPA-REG OUTCOME Study? A Unifying Hypothesis

Regulation of Substrate Utilization by the Mitochondrial Pyruvate Carrier

Efficacy of GLP-1 Receptor Agonists and DPP-4 Inhibitors: Meta-Analysis and Systematic Review

Exploring the potential of the SGLT2 inhibitor dapagliflozin in type 1 diabetes: a randomized, double-blind, placebo-controlled pilot study

Altered Myokine Secretion Is an Intrinsic Property of Skeletal Muscle in Type 2 Diabetes

AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY POSITION STATEMENT ON THE ASSOCIATION OF SGLT-2 INHIBITORS AND DIABETIC KETOACIDOSIS

American association of clinical endocrinologists and american college of endocrinology - clinical practice guidelines for developing a diabetes mellitus comprehensive care plan - 2015

Thiazolidinediones are acute, specific inhibitors of the mitochondrial pyruvate carrier

Uromodulin mRNA from Urinary Extracellular Vesicles Correlate to Kidney Function Decline in Type 2 Diabetes Mellitus

Astaxanthin, a natural antioxidant, lowers cholesterol and markers of cardiovascular risk in individuals with prediabetes and dyslipidaemia

Retinol-Binding Protein 4 and Insulin Resistance in Lean, Obese, and Diabetic Subjects

Adiponectin: More than just another fat cell hormone?

Adiponectin in health and disease

Effects of Exenatide (Exendin-4) on Glycemic Control Over 30 Weeks in Sulfonylurea-Treated Patients With Type 2 Diabetes

Apolipoprotein J is a hepatokine regulating muscle glucose metabolism and insulin sensitivity

Efficacy and Safety of Canagliflozin, a Sodium-Glucose Cotransporter 2 Inhibitor, as Add-on to Insulin in Patients With Type 1 Diabetes

Improved glycemic control with minimal systemic metformin exposure: Effects of Metformin Delayed-Release (Metformin DR) targeting the lower bowel over 16 weeks in a randomized trial in subjects with type 2 diabetes

Effect of the dual peroxisome proliferator-activated receptor-α/γ agonist aleglitazar on risk of cardiovascular disease in patients with type 2 diabetes (SYNCHRONY): a phase II, randomised, dose-ranging study

Sodium-Glucose Cotransporter Inhibitors: Effects on Renal and Intestinal Glucose Transport: From Bench to Bedside

(−)-Epicatechin rich cocoa mediated modulation of oxidative stress regulators in skeletal muscle of heart failure and type 2 diabetes patients

SGLT2 inhibition — a novel strategy for diabetes treatment

Poor medication adherence in type 2 diabetes: recognizing the scope of the problem and its key contributors

Myokine Regulation of Insulin Secretion: Impact of Inflammation and Type 2 Diabetes

Effects of (−)-epicatechin on molecular modulators of skeletal muscle growth and differentiation

SGLT inhibitor adjunct therapy in type 1 diabetes

Aktive Filter

Suchergebnisse filtern